Login to Your Account

‘Sprucing’ up the place: $20M series A takes lead asset into phase II in CAH

By Marie Powers
News Editor

Thursday, October 12, 2017

Spruce Biosciences Inc. landed a $20 million series A last year but kept the financing under wraps, waiting for its only asset, SPR-001, to achieve its first clinical milestone.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription